Get the content you want anytime you want.
REGISTER NOW | SIGN IN
VIDEO

Is Cabotegravir a Gender-Neutral PrEP Medication?

AUG 24, 2017 | CONTAGION® EDITORIAL STAFF


Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains studies that are underway involving how effective the PrEP medication cabotegravir is in men who have sex with men as well as transgendered women. Dr. Rinehart stresses that he and his team are trying to study efficacy in all relevant key populations affected by HIV.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.